Accelleron Industries AG General Assembly 2023: All Proposals Receive Approval
The shareholders of Accelleron Industries AG have approved all proposals of the Board of Directors with a large majority on the occasion of the first Annual General Meeting today.
At the first Annual General Meeting of Accelleron Industries AG, the shareholders approved all proposals, including the total maximum aggregate of compensation for the members of the Board of Directors for the period from the Annual General Meeting 2023 to the Annual General Meeting 2024 and the maximum aggregate amount of compensation for the members of the Executive Committee for the financial year 2024, in each case by a large majority.
The proposed dividend for the financial year 2022 was approved by a large majority. Shareholders will receive a distribution in the form of a dividend of CHF 0.73 gross per share.
All the proposed members of the Board of Directors were confirmed. Oliver Riemenschneider was re-elected as Chairman of the Board of Directors with a large majority. A total of 55,863,682 registered shares with voting rights were represented at the Annual General Meeting of Accelleron Industries AG, representing 59.12 % of the share capital entered in the share register with voting rights.
Accelleron is a leading global supplier of turbochargers and optimization solutions for engines from 0.5 to 80+ MW, helping to provide sustainable, efficient and reliable energy to the marine, energy, rail and off-highway sectors. Through its innovative product offering and research leadership, the company is accelerating the decarbonization of the industries in which it operates. Accelleron has an installed base of approximately 180,000 turbochargers and a network of more than 100 service stations in 50 countries worldwide (www.accelleron-industries.com).
|May 23, 2023||
Ex date for dividend payment
|May 25, 2023||
Distribution of the dividend
|September 5, 2023||
Publication of half-year report 2023
Information for the media
Images and other digital content are available at www.accelleron-industries.com.
Accelleron sharesThe registered shares of Accelleron Industries AG are listed on the SIX Swiss Exchange, Zurich, under the ticker symbol "ACLN" (ISIN: CH1169360919 / Swiss security number: 116936091).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509006003/en/
Contact for the media:
Head of External Communications and Public Affairs
Phone: +41 79 627 63 88
Contact for investors:
Vice President Strategy & IR
Phone: +41 79 698 6085
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Patient Safety Movement Foundation Concludes Its 10th Annual World Patient Safety, Science & Technology Summit3.6.2023 08:11:00 EEST | Press release
President Bill Clinton, 42nd President of the United States, headlined day two of the 10th Annual World Patient Safety, Science & Technology Summit, presented by the Patient Safety Movement Foundation (PSMF). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230602005417/en/ Joe Kiani, founder of the Patient Safety Movement Foundation, discusses efforts to improve patient safety worldwide with former President Bill Clinton at the 10th Annual World Patient Safety, Science & Technology Summit in Newport Beach, California. (Photo: Business Wire) As a long-time advocate of patient safety, President Clinton spoke of the need to develop what he termed a “culture of conversion,” where more people within healthcare feel empowered to implement proven practices for eliminating preventable harm within hospitals. “We know enough right now to cut the current problem by half or more,” he said. “One of the biggest problems you have in every b
Ilsong Educational Foundation Chairman Dai-Won Yoon Wins Linnaeus Medal as the First in Asia2.6.2023 12:00:00 EEST | Press release
On May 30, Chairman Dai-Won Yoon of Ilsong Educational Foundation received the Linnaeus Medal from Uppsala University at Hallym University. This makes him the first person from Asia to receive the award. Ilsong Educational Foundation operates Hallym University and Hallym University Medical Center. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531005495/en/ Chairman Dai-Won Yoon (left) of Ilsong Educational Foundation received Linnaeus Medal as the 1st in Asia (Photo: Hallym University) Chairman Yoon is the honoree of 2020. The award ceremony, which had been postponed due to COVID-19, was held this year with a delegation led by Vice Chancellor Anders Hagfeldt of Uppsala University visiting Korea. The Linnaeus Medal to commemorate Carl Linnaeus, a Swedish botanist, is awarded annually by Uppsala University to a person who has made a significant contribution to the field of science. Chairman Yoon was honored for his work in
10th Annual World Patient Safety, Science & Technology Summit Begins2.6.2023 09:15:00 EEST | Press release
Day one of the 10th Annual World Patient Safety, Science & Technology Summit presented by the Patient Safety Movement Foundation (PSMF) saw global leaders across the world of patient safety call for an increased urgency in addressing the issue of preventable harm within healthcare. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601006140/en/ Joe Kiani, founder of the Patient Safety Movement Foundation, speaks at the 10th Annual World Patient Safety, Science & Technology Summit in Newport Beach, California. (Photo: Business Wire) Celebrating the PSMF’s 10th anniversary, Dr. Michael Ramsay, chief executive officer of the PSMF, reflected on the role that the increasing availability of hospital data on medical errors could play in reducing harm. “I’m very optimistic that we’re really going to see a difference in healthcare,” he said. “Technology is changing. We’re now getting real data. We know what the outcomes are in hospit
Autel Energy Holds Partner Summit in Amsterdam, Mapping Out Europe Strategy2.6.2023 09:00:00 EEST | Press release
Autel Energy, a leading provider of EV charging products and services, successfully hosted the Autel Partner Summit at Muziekgebouw in Amsterdam from May 31 to June 1, 2023. The event not only showcased Autel’s visionary Europe strategy for the next two years but also provided partners opportunities to gain insights into the company's vision, and learn about Autel’s new products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005428/en/ A quick afternoon bite with the Autel partners. (Photo: Business Wire) The Partner Summit helped Autel Energy to strengthen its partnerships in Europe and highlighted its collaborations with key clients. Notable partners in attendance included Maxicharger AC clients such as Sevadis and Deta, as well as Maxicharger DC clients such as Floading, Gasgas, and eWays. The company also partnered with CPO clients like Fastway and Powerdo, as well as energy companies like Enefit. The Summit was d
PL BioScience and Macopharma enter into a Patent License and Assignment Agreement regarding Human Platelet Lysate (HPL) cell culture supplements.2.6.2023 08:22:00 EEST | Press release
PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a Patent License and Assignment Agreement with the French company Macopharma S.A.S. As a result of the Agreement, PL BioScience will hereby accept a worldwide license under the patents filed by Macopharma, with a right to sublicense (through multiple tiers), for the duration of the license period. In addition to the Patent License and Assignment Agreement, Macopharma will introduce PL BioScience to their current HPL customers, and thanks to a comprehensive comparative evaluation showing equivalence of HPL products from PL BioScience, Macopharma HPL customers will have the opportunity to transfer their future orders to PL BioScience with minimal disruption. About PL BioScience: Located in Aachen in Germany, PL BioScience GmbH is a life science company specializing in the production and development of Human Platelet Lysate (HP
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom